

CITATION REPORT

List of articles citing

Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis

DOI: 10.1097/cnd.0000000000000316

Journal of Clinical Neuromuscular Disease, 2020, 22, 60-62.

Source: <https://exaly.com/paper-pdf/76132071/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Hydroxychloroquine. <i>Reactions Weekly</i> , 2020 , 1823, 189-189	0	0
17	Putative mechanisms explaining neuro-COVID. <i>Journal of Neuroimmunology</i> , 2020 , 350, 577453	3.5	2
16	Comprehensive work-up is warranted for patients with severe COVID-19 and muscle weakness including respiratory muscles. <i>Clinical Neurophysiology</i> , 2021 , 132, 692-693	4.3	3
15	Perspectives of Neuro-COVID: Myasthenia. <i>Frontiers in Neurology</i> , 2021 , 12, 635747	4.1	2
14	Reply to "Comprehensive work-up is warranted for patients with severe COVID-19 and muscle weakness including respiratory muscles". <i>Clinical Neurophysiology</i> , 2021 , 132, 694-695	4.3	0
13	[Neuromuscular complications of SARS-CoV-2 infections-Part 1: peripheral nerves]. <i>Der Nervenarzt</i> , 2021 , 92, 540-547	0.5	0
12	MuSK-positive myasthenia may be triggered not only by SARS-CoV-2. <i>European Journal of Neurology</i> , 2021 , 28, e80-e81	6	1
11	Clinical and Pathophysiologic Spectrum of Neuro-COVID. <i>Molecular Neurobiology</i> , 2021 , 58, 3787-3791	6.2	10
10	Neurological Complications of COVID-19: Underlying Mechanisms and Management. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	12
9	Use of Remdesivir in Myasthenia gravis and COVID-19. <i>Pharmacotherapy</i> , 2021 , 41, 546-550	5.8	2
8	SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm That Implicates For Therapeutic Strategies. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	1
7	COVID-19 in patients with myasthenia gravis: Epidemiology and disease course. <i>Muscle and Nerve</i> , 2021 , 64, 206-211	3.4	11
6	Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	7
5	Intensive Care Unit-Acquired Weakness and the COVID-19 Pandemic: A Clinical Review.. <i>PM and R</i> , 2022 ,	2.2	1
4	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
3	Not the Virus but Treatment and Immune Response Cause SARS-CoV-2-associated Neuropathy. 2022 , 26, 980-980		
2	Clinical course and outcome of Covid-19 in patients with myasthenia gravis. 1-7		0

1 The Latest Cellular and Molecular Mechanisms of COVID-19 on Non-Lung Organs. **2023**, 13, 415

o